<DOC>
	<DOCNO>NCT02127073</DOCNO>
	<brief_summary>The purpose study examine genetic material call microRNA three type specimens woman breast cancer . The study also seek examine effectiveness use new agent call oxytocin increase amount nipple fluid collect surgery .</brief_summary>
	<brief_title>Pilot Study Oxytocin microRNA Identification NAF , Serum , Tissue Women With Breast Cancer</brief_title>
	<detailed_description>Vast majority breast cancer arise ductal epithelium . Ductal cell collect nipple orifice early breast cancer development . The nipple aspirate ﬂuid ( NAF ) use identify biomarkers predict risk breast cancer . To date , biomarkers identify nipple aspirate ﬂuid ( NAF ) limit utility due large volume NAF require data analysis . Recent study show intranasal oxytocin 's utility enhance yield nipple aspirate ﬂuid ( NAF ) among healthy , non-lactating female patient well high risk breast cancer . This capability crucial analysis various marker associate breast disease cancer microRNAs . The primary aim study determine whether microRNA profile characterization feasible collection tissue , serum NAF patient situ invasive breast cancer . Intranasal oxytocin use enhance ﬂuid yield NAF .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Clinical diagnosis Ductal carcinoma situ ( DCIS ) invasive breast cancer Candidate breast conserving surgery mastectomy Pregnant woman Prior Breast Cancer diagnosis Adverse reaction Oxytocyn past</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Ductal carcinoma situ ( DCIS )</keyword>
	<keyword>Oxytocin</keyword>
</DOC>